"studyDesignRationale","bcCategories","studyEstimands","description","label","studyInvestigationalInterventions","uuid:ID","documentVersion","id","name"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","[]","[]","The main design for the study","","[]","3af70871-4529-4011-980c-ca3cb8e7e2b2","","StudyDesign_1","Study Design 1"
